Omalizumab for treating severe persistent allergic asthma

Review proposal consultation

Stakeholder matrix (MSWord 33 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): equality impact assessment - guidance development

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): final appraisal determination information

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): final appraisal determination document

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): final appraisal determination document (PDF 259 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 221 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): consultee and commentator coments on the ACD

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Novartis

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Novartis response

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Novartis response (PDF 199 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Novartis additional cost-effectiveness analyses

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Novartis additional cost-effectiveness analyses (PDF 120 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Asthma UK

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Asthma UK (PDF 122 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): British Society for Allergy and Clinical Immunology

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): British Society for Allergy and Clinical Immunology (PDF 45 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): British Thoracic Society

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): British Thoracic Society (PDF 358 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Royal College of Nurses

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Royal College of Nurses (PDF 23 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Royal College of Paediatrics and Child Heath

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Royal College of Paediatrics and Child Heath (PDF 134 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Royal College of Pathologists

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Royal College of Pathologists (PDF 79 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): United Kingdom Clinical Pharmacy Association

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): United Kingdom Clinical Pharmacy Association (PDF 87 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Department of Health

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Department of Health (PDF 37 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Healthcare Improvement Scotland

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Healthcare Improvement Scotland (PDF 31 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): comments on the ACD received from the public through the NICE website

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): comments on the ACD received from the public through the NICE website (PDF 165 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Assessment Group's additional analyses

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): EIA form (scoping)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): appraisal consultation

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): appraisal consultation document information

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): evaluation report

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): overview

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): overview (PDF 382 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): assessment report

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): assessment report (PDF 1.8 MB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): consultee and commentator comments on the assessment report

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Asthma UK

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Asthma UK (PDF 34 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Royal College of Nursing

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Royal College of Nursing (PDF 6.5 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): British Society for Allergy and Clinical Immunology

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): British Society for Allergy and Clinical Immunology (PDF 52 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): British Thoracic Society

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): British Thoracic Society (PDF 6.6 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Royal College of Paediatrics and Child Health

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Royal College of Paediatrics and Child Health (PDF 30 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): United Kingdom Clinical Pharmacy Association

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): United Kingdom Clinical Pharmacy Association (PDF 70 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Department of Health

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Department of Health (PDF 6.4 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Healthcare Improvement Scotland

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Healthcare Improvement Scotland (PDF 26 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): response to consultee and commentator comments on the assessment report

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): response to consultee and commentator comments on the assessment report (PDF 245 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Novartis

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Novartis (PDF 341 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): non-manufacturer submissions

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Association of Respiratory Nurses

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Association of Respiratory Nurses (PDF 76 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Asthma UK

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Asthma UK (PDF 636 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): British Society for Allergy and Clinical Immunology

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): British Society for Allergy and Clinical Immunology (PDF 89 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): British Thoracic Society

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): British Thoracic Society (PDF 69 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Royal College of Physicians

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Royal College of Physicians (PDF 6.4 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Primary Care Respiratory Society

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Primary Care Respiratory Society (PDF 56 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Royal College of Nurses

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Royal College of Nurses (PDF 23 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Royal College of Paediatrics and Child Health

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Royal College of Paediatrics and Child Health (PDF 46 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): United Kingdom Clinical Pharmacy Association

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): United Kingdom Clinical Pharmacy Association (PDF 74 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Department of Health

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Department of Health (PDF 9.9 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): expert written personal statements

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Nasser

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Nasser (PDF 16 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Roberts

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Roberts (PDF 13 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Humphreys

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Humphreys (PDF 22 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Whitehead

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Whitehead (PDF 366 KB)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Thompson

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): assessment report

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): letter to Consultees and Commentators regarding the Committee's request for additional analyses

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): final protocol

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): final matrix

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): final scope

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): response to comments on the provisional matrix

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): response to comments on the draft scope

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): draft scope

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): provisional matrix